IBD Rates Low in Patients on Cosentyx

ncidence rates of inflammatory bowel disease (IBD) among patients being treated with secukinumab (Cosentyx) for rheumatic inflammatory diseases were low, pooled clinical trial data indicated.

Source: IBD Rates Low in Patients on Cosentyx

About the Author

Stephanie Figon, MS, RDN, LD

Creator of Supplement Sciences and NutriScape.NET. As a dietitian since 1992, Steph has had experiences in consulting, 15 years in clinical, and has operated a private practice nutrition counseling office for since 2011. Log in to comment and save this article on your board or send your comments to reviews@supplement-sciences.com